Innovation1 Biotech Inc. (IVBT)

USD 0.0

(0.0%)

Net Debt Summary of Innovation1 Biotech Inc.

Innovation1 Biotech Inc.'s latest annual net debt in 2023 was 179.15 Thousand USD , down -48.98% from previous year.
Innovation1 Biotech Inc.'s latest quarterly net debt in 2023 FY was 179.15 Thousand USD , down -48.98% from previous quarter.
Innovation1 Biotech Inc. reported annual net debt of 351.14 Thousand USD in 2022, up 1458.96% from previous year.
Innovation1 Biotech Inc. reported annual net debt of 22.52 Thousand USD in 2021, down -97.26% from previous year.
Innovation1 Biotech Inc. reported quarterly net debt of 179.15 Thousand USD for 2023 FY, down -48.98% from previous quarter.
Innovation1 Biotech Inc. reported quarterly net debt of 179.15 Thousand USD for 2023 Q4, up 306.28% from previous quarter.

Annual Net Debt Chart of Innovation1 Biotech Inc. (2023 - 2015)

Historical Annual Net Debt of Innovation1 Biotech Inc. (2023 - 2015)

Year	Net Debt	Net Debt Growth
2023	179.15 Thousand USD	-48.98%
2022	351.14 Thousand USD	1458.96%
2021	22.52 Thousand USD	-97.26%
2020	823.28 Thousand USD	1329.97%
2019	57.57 Thousand USD	107.94%
2018	-724.96 Thousand USD	-14765.04%
2017	-4877.00 USD	-122.09%
2016	22.07 Thousand USD	3861.33%
2015	-587.00 USD	0.0%

Year	Net Debt	Net Debt Growth
2023 Q1	-20.11 Thousand USD	-104.46%
2023 FY	179.15 Thousand USD	-48.98%
2023 Q4	179.15 Thousand USD	306.28%
2023 Q3	44.09 Thousand USD	0.0%
2023 Q2	44.09 Thousand USD	319.23%
2022 Q3	-81.75 Thousand USD	88.49%
2022 Q1	-2.92 Million USD	-13080.43%
2022 FY	351.14 Thousand USD	1458.96%
2022 Q2	-710.25 Thousand USD	75.71%
2022 Q4	451 Thousand USD	651.66%
2021 Q2	930.47 Thousand USD	4.3%
2021 Q4	22.52 Thousand USD	206.24%
2021 FY	22.52 Thousand USD	-97.26%
2021 Q3	-21.2 Thousand USD	-102.28%
2021 Q1	892.13 Thousand USD	8.36%
2020 Q1	162.98 Thousand USD	183.09%
2020 FY	823.28 Thousand USD	1329.97%
2020 Q4	823.28 Thousand USD	-7.76%
2020 Q3	892.54 Thousand USD	39.53%
2020 Q2	639.66 Thousand USD	292.46%
2019 Q1	-197.12 Thousand USD	72.81%
2019 FY	57.57 Thousand USD	107.94%
2019 Q4	57.57 Thousand USD	61.88%
2019 Q3	35.56 Thousand USD	230.36%
2019 Q2	-27.28 Thousand USD	86.16%
2018 Q4	-724.96 Thousand USD	-2556.94%
2018 FY	-724.96 Thousand USD	-14765.04%
2018 Q3	29.5 Thousand USD	397.42%
2018 Q1	-40 Thousand USD	-720.18%
2018 Q2	5932.00 USD	114.83%
2017 FY	-4877.00 USD	-122.09%
2017 Q1	-473.00 USD	90.74%
2017 Q3	-401.00 USD	-109.95%
2017 Q2	-191.00 USD	59.62%
2017 Q4	-4877.00 USD	-1116.21%
2016 Q1	-3856.00 USD	-556.9%
2016 Q4	-5108.00 USD	-0.02%
2016 Q3	-5107.00 USD	-373.31%
2016 Q2	-1079.00 USD	72.02%
2016 FY	22.07 Thousand USD	3861.33%
2015 FY	-587.00 USD	0.0%
2015 Q4	-587.00 USD	0.0%

Peer Net Debt Comparison of Innovation1 Biotech Inc.

Name	Net Debt	Net Debt Difference
America Great Health	1.81 Million USD	90.136%
Gene Biotherapeutics, Inc.	- USD	-Infinity%
Evolutionary Genomics, Inc.	3.16 Million USD	94.343%
Point of Care Nano-Technology, Inc.	-498.00 USD	36073.896%
Vicapsys Life Sciences, Inc.	344.44 Thousand USD	47.989%